LivaNova (NASDAQ:LIVN) Raised to “Strong-Buy” at StockNews.com

LivaNova (NASDAQ:LIVN) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday.

LIVN has been the topic of several other research reports. The Goldman Sachs Group dropped their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Barclays dropped their target price on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. Mizuho decreased their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus lowered their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of LivaNova in a report on Monday, March 17th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $61.17.

LivaNova Stock Down 1.1 %

Shares of LivaNova stock traded down $0.45 during trading hours on Tuesday, reaching $39.92. The company’s stock had a trading volume of 458,433 shares, compared to its average volume of 595,299. The company has a market capitalization of $2.17 billion, a P/E ratio of 95.05 and a beta of 1.10. The stock’s fifty day simple moving average is $45.01 and its two-hundred day simple moving average is $48.65. LivaNova has a one year low of $36.85 and a one year high of $64.48. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. raised its stake in shares of LivaNova by 62.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares during the period. Freestone Grove Partners LP bought a new stake in LivaNova in the fourth quarter worth about $23,102,000. Artisan Partners Limited Partnership purchased a new position in LivaNova in the fourth quarter valued at about $21,340,000. The Manufacturers Life Insurance Company grew its position in shares of LivaNova by 163.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company’s stock valued at $25,303,000 after acquiring an additional 339,139 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of LivaNova by 79.3% during the 4th quarter. AQR Capital Management LLC now owns 742,180 shares of the company’s stock worth $34,214,000 after purchasing an additional 328,313 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.